ENVB
Enveric Biosciences, Inc.·Healthcare
2.18
2.135%(−0.05)
Market OpenLast Updated: — ET
52W L: $1.7152W H: $17.64
ENVB NEWS
businesswire.com
May 19
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced promising results from preclinical in vitro experiments evaluating the risk for phototoxicity, which indicated no photoreactive potential for EB-003, further derisking its continued development for the chronic treatment of neuropsychiatric disorde.
gurufocus.com
May 15
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
Enveric Biosciences (NASDAQ: ENVB) (âEnvericâ or the âCompanyâ), a biotechnology company advancing next-generation neuroplastogenic small molecules to
businesswire.com
May 15
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2026, and provided a comprehensive business update. CEO Commentary: “Our progress in the first quarter of 2026 reflects continued execution against our core mission of developing therapeutics ca.
businesswire.com
May 13
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the United States Patent and Trademark Office (USPTO) issued to Enveric US Patent No. 12,605,361 (the '361 patent), titled, “Carboxylated Psilocybin Derivatives and Methods of Using,” pertaining to the Company's EVM301 Series of molecules bei.
businesswire.com
May 5
Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today highlighted preclinical data for its lead candidate, EB-003, a dual 5-HT2A and 5-HT1B modulator, in which a single dose of EB-003 significantly reduced context-induced freezing behavior one hour post-dose (p < 0.05). These results indicate a rapid reduct.
prnewswire.com
Apr 28
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
Appointment strengthens Board with seasoned public company biotech executive following recent Nasdaq direct listing SARASOTA, Fla., April 28, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the appointment of Joseph Tucker, Ph.D.
